-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, HdxdpesckLavtZ81zHcpOzNdrYUvoo2ctYYHAZd4ZxYHgzVbClJyxHGDvT3zMK7X 1YkrJdUpkCvfpEg0zcb9IQ== 0001104659-05-041329.txt : 20050825 0001104659-05-041329.hdr.sgml : 20050825 20050825153349 ACCESSION NUMBER: 0001104659-05-041329 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20050824 ITEM INFORMATION: Other Events FILED AS OF DATE: 20050825 DATE AS OF CHANGE: 20050825 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CERUS CORP CENTRAL INDEX KEY: 0001020214 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 680262011 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-21937 FILM NUMBER: 051048793 BUSINESS ADDRESS: STREET 1: 2411 STANWELL DR CITY: CONCORD STATE: CA ZIP: 94520 BUSINESS PHONE: 9252886000 MAIL ADDRESS: STREET 1: 2525 STANWELL DRIVE STREET 2: STE 300 CITY: CONCORD STATE: CA ZIP: 94520 FORMER COMPANY: FORMER CONFORMED NAME: CERUS TECHNOLOGIES INC DATE OF NAME CHANGE: 19960731 8-K 1 a05-15431_18k.htm 8-K

 

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported):  August 24, 2005

 

CERUS CORPORATION

(Exact name of registrant as specified in its charter)

 

Delaware

 

0-21937

 

68-0262011

(State of jurisdiction)

 

(Commission File No.)

 

(IRS Employer Identification No.)

 

2411 Stanwell Drive

Concord, California 94520

(Address of principal executive offices and zip code)

 

Registrant’s telephone number, including area code: (925) 288-6000

 



 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

o    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

o    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

o    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

o    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e 4(c))

 

 


 

Item 8.01.  Other Events.

 

On August 24, 2005, Cerus Corporation (the “Company”) was notified that the French Official Journal (Le Journal Officiel de la République Française) published a decree of the French Ministry of Health and Welfare (Le Ministère de la Santé et des Solidarités) registering the following blood product listings:

 

•       Pooled leukodepleted platelet concentrate treated with Amotosalen for pathogen inactivation; and

 

•       Leukodepleted apheresis platelet concentrate treated with Amotosalen for pathogen inactivation.

 

(Amotosalen is a proprietary compound of the Company and is contained in its INTERCEPT Blood System for platelets.)

 

As a result of the decree, the Company believes that it has received final French regulatory approval for the use of the INTERCEPT Blood System for platelets in France.  Furthermore, the Company believes that its commercialization partner, Baxter Healthcare Corporation, may negotiate reimbursement levels for the use of the INTERCEPT Blood System for platelets with French authorities responsible for reimbursement, and may market the INTERCEPT Blood System for platelets with French blood center customers.  The Company does not expect to receive any substantial revenues from the sale of the INTERCEPT Blood System for platelets in France until reimbursement levels have been established, and the Company cannot predict whether or when purchasing decisions may be made by French blood center customers.

 

2


 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

CERUS CORPORATION

 

 

 

 

 

 

Dated:    August 25, 2005

By:

/s/ William J. Dawson

 

 

William J. Dawson

 

 

Vice President, Finance and Chief

 

 

Financial Officer

 

3

 -----END PRIVACY-ENHANCED MESSAGE-----